Design and Synthesis oftrans-3-(2-(4-((3-(3-(5-Methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro- 1H-3-benzazepine (SB-414796): A Potent and Selective Dopamine D3Receptor Antagonist
- 15 October 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (23) , 4952-4964
- https://doi.org/10.1021/jm030817d
Abstract
At their clinical doses, current antipsychotic agents share the property of both dopamine D2 and D3 receptor blockade. However, a major disadvantage of many current medications are the observed extrapyramidal side-effects (EPS), postulated to arise from D2 receptor antagonism. Consequently, a selective dopamine D3 receptor antagonist could offer an attractive antipsychotic therapy, devoid of the unwanted EPS. Using SAR information gained in two previously reported series of potent and selective D3 receptor antagonists, as exemplified by the 2,3,4,5-tetrahydro-1H-3-benzazepine 10 and the 2,3-dihydro-1H-isoindoline 11, a range of 7-sulfonyloxy- and 7-sulfonylbenzazepines has been prepared. Compounds of this type combined a high level of D3 affinity and selectivity vs D2 with an excellent pharmacokinetic profile in the rat. Subsequent optimization of this series to improve selectivity over a range of receptors and reduce cytochrome P450 inhibitory potential gave trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxidiazolyl))phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (58, SB-414796). This compound is a potent and selective dopamine D3 receptor antagonist with high oral bioavailability and is CNS penetrant in the rat. Subsequent evaluation in the rat has shown that 58 preferentially reduces firing of dopaminergic cells in the ventral tegmental area (A10) compared to the substantia nigra (A9), an observation consistent with a prediction for atypical antipsychotic efficacy. In a separate study, 58 has been shown to block expression of the conditioned place preference (CPP) response to cocaine in male rats, suggesting that it may also have a role in the treatment of cue-induced relapse in drug-free cocaine addicts.Keywords
This publication has 16 references indexed in Scilit:
- Dopamine D3Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in RatsJournal of Neuroscience, 2002
- Dopamine D3 Receptor Antagonists. 1. Synthesis and Structure−Activity Relationships of 5,6-Dimethoxy-N-alkyl- and N-Alkylaryl-Substituted 2-AminoindansJournal of Medicinal Chemistry, 2001
- Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptorBioorganic & Medicinal Chemistry Letters, 2001
- Design and Synthesis of trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2- yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A Potent and Selective Dopamine D3 Receptor Antagonist with High Oral Bioavailability and CNS Penetration in the RatJournal of Medicinal Chemistry, 2000
- Novel cyclohexyl amides as potent and selective D3 dopamine receptor ligandsBioorganic & Medicinal Chemistry Letters, 1997
- Linking the Family of D2 Receptors to Neuronal Circuits in Human Brain: Insights into SchizophreniaNeuropsychopharmacology, 1997
- 2-[(substituted)phenyl]-5-[1-(2-phenylazacycloheptyl)methyl]-1H-pyrroles with high affinity and selectivity for the dopamine D3 receptorBioorganic & Medicinal Chemistry Letters, 1997
- Dopamine D3 Receptor: Basic and Clinical AspectsClinical Neuropharmacology, 1993
- Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neurolepticsNature, 1990
- Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine NeuronsScience, 1983